Clinical overview of mesna

Cancer Treatment Reviews

Volumn 10, Issue SUPPL. 1, 1983, Pages 175-181

  Burkert, Hans ^a  

^a ASTA Werke AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; IFOSFAMIDE; MESNA; METHOTREXATE; OXAZAPHOSPHORINE; PREDNISONE; TEGAFUR; TROFOSFAMIDE; VINBLASTINE; VINCRISTINE;

ADVERSE DRUG REACTION; BLADDER; CANCER CHEMOTHERAPY; DRUG INTERACTION; HEMATURIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NAUSEA; ORAL DRUG ADMINISTRATION; PREVENTION; SHORT SURVEY; THERAPY; VOMITING;

CLINICAL TRIALS; CYCLOPHOSPHAMIDE; DRUG INTERACTIONS; HEMATURIA; HUMAN; IFOSFAMIDE; MERCAPTOETHANOL; MESNA; NEOPLASMS;

EID: 0021089713     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-7372(83)80026-7     Document Type: Article

References (25)

1. Chemotherapy of lung cancer and protection of urotoxicity with Uromitexan
2. Phase II evaluation of ifosfamide in refractory malignant diseases: comparison of the uroprotective effect of mesna with forced diuresis plus alkalinization of urine
3. Detoxification of urotoxic oxazaphosphorines by sulfhydryl compounds
4. Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention. I. Experimental studies on the urotoxicity of alkylating compounds
5. Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention. 2. Comparative study on the uroprotective efficacy of thiols and other sulfur compounds
6. High-dose cyclophosphamide therapy for malignant disease.Toxicity, tumor response, and the effects of stored autologous marrow
7. New experience with the oxazaphosphorines with special reference to the uroprotector Uromitexan®
8. Verhütung der Harnwegstoxizität von Oxazaphosphorinen durch einen “Uroprotektor”. Bericht über eine Feldstadie
9. Histologische Organveränderungen beim Kaninchen nach Gaben von Prednisolon und Endoxan
10. Erfahrungen mit der fraktionierten Ifosfamid-Stoßtherapie bei generalisierten malignen Tumoren
11. Urinary-bladder toxicity following pelvic irradiation and simultaneous cyclophosphamide therapy
12. Prevention of genito-urinary toxicity of ifosfamide with Na 2-mercaptocthane sulfonate (mesna)
13. Cyclophosphamide-induced hemorrhagic cystitis exacerbated by melphalan
14. Cyclophosphamide and urinary bladder toxicity
15. Zur Pharmakokinetik von Uromitexan
16. Controlled clinical studies with an antidote against the urotoxicity of oxazaphosphorines: preliminary results
17. The treatment of solid malignant tumours with Holoxan and Uromitexan
18. Clinical experience with mesna (Uromitexan)
19. Erste klinische Erfahrungen mit ultrahohen Einzeldosen von Cyclophosphamid
20. Folgen am harnbereitenden und harnableitenden System während Cyclophosphamid-Therapie
21. Zur Pathogenese, Klinik und Prophylaxe der sogenannten Cyclophosphamid-Zystitis
22. Ifosfamide treatment with and without the uroprotective agent mesna
23. Oral sodium 2-mercaptoethane sulfonate (mesna, Uromitexan) in ifosfamide therapy: preliminary report